BEXMAB Study Update
Faron Pharmaceuticals Oy (“Faron” or “Company”) Inside Information: Promising start to a new study investigating bexmarilimab for the treatment of hematological malignancies – BEXMAB Study Update · Dose escalation to the second predefined level in first clinical study to investigate bexmarilimab in hematological malignancies · No dose-limiting toxicities or safety concerns observed among five patients to have received initial dose at 1 mg/kg every week · Early signs of efficacy with partial response observed in one patient after three dosing cycles · New